New product: Adtralza (tralokinumab) 150 mg solution for injection in pre-filled syringe

Tralokinumab, an IgG4 monoclonal antibody that specifically binds to interleukin-13, is licensed for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

Source:

electronic Medicines compendium